Author: Editor

There is not a large amount of data available to allow clinicians to determine whether patients should remain on or cease venetoclax treatment. In this interview, Constantine Tam, MD, FRACP, FRCPA, of Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the issue. Dr Tam highlights data from a study of chronic lymphocytic leukemia (CLL) patients using a combination of venetoclax and rituximab, in which several patients ceased treatment. He also presents the logical case of treatment cessation in terms of hindering drug resistance. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta,…

Following the completion of the initial stages of the KEYNOTE-045 trial of pembrolizumab vs. the standard care for advanced urothelial cancer following chemotherapy (NCT02256436), clinicians have been awaiting the follow-up results to determine the level of benefit pembrolizumab treatment brings. At the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, the 2-year follow-up data from this study was presented, as discussed here by Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK. Prof. Jones highlights the continuing positive results observed and discusses the subgroup of patients showing great survival benefit, comparing…

The current standard of care for frontline kidney cancer is tyrosine kinase inhibitor (TKI) treatment. Now there are a host of promising immune checkpoint inhibitors in trials for this indication, either alone or in combination with TKIs. In this interview, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the Phase III randomized IMmotion151 trial of bevacizumab and atezolizumab vs. sunitinib for advanced renal cell carcinoma (NCT02420821). Prof. Jones discusses the rationale behind the combination, the trial cohort and the results thus far. He also mentions other up-and-coming checkpoint inhibitor-TKI combinations…

The UK was well represented at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. In this video, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the Phase III Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer trial (POUT; NCT01993979). Prof. Jones emphasizes the importance of this trial, in both the type of cancer studied and the practice-changing potential of the results.

Long-term follow-up data is the real determinant of the efficacy of novel therapies. Here, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses what the promising 2-year follow-up data from the KEYNOTE-045 trial of pembrolizumab for advanced urothelial cancer (NCT02256436) tells us moving forwards. Prof. Jones contemplates the indications and patients in which pembrolizumab may be used, as well as those where it wouldnt provide a significant benefit. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the sequencing and uses of enzalutamide are being explored, in order to maximize its utility. In this interview, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the exciting head-to-head prospective comparator trial of enzalutamide vs. abiraterone acetate plus prednisone for M1 CRPC patients prior to receiving chemotherapy, which assessed tolerability in a real-world setting. Dr Shore covers the aims, design and interesting results of the study so far. This video was recorded at the 2018 Genitourinary…

The addition of a new prostate cancer diagnostic test to inform clinicians and patients prior to the decision to biopsy would be beneficial, in conjunction with the traditional measures of PSA and DRE. In this interview, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, gives us an overview of the MiCheck MIA test for differentiating aggressive from non-aggressive prostate cancer. Dr Shore explains how this test measures glypican-1 (GPC1) and related biomarker levels, and discusses how this parameter could impact the management of prostate cancer. This video was recorded at the 2018 Genitourinary Cancers Symposium, held…

Previously, patients with nonmetastatic castration-resistant prostate cancer (nmCRPRC) and the clinicians treating them had no therapeutic options to delay disease progression. Now there are two new non-steroidal anti-androgens, apalutamide and enzalutamide, on the horizon. Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the Phase III trials of these drugs, SPARTAN (NCT01946204) and PROSPER (NCT02003924), and forecasts how he expects the results of these to impact clinical practice.

There has previously been no approved treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC), due to a lack of evidence that any drug would prevent disease progression in this population; now this may change. Here, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the Phase III randomized, prospective PROSPER trial (NCT02003924) of enzalutamide for nmCRPRC. Dr Shore discusses the rationale, aims, design and results of the trial, as well as the approved indications and evidence for the use of enzalutamide. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

This interview provides an exciting insight into the Translational Research Training in Hematology (TRTH) and the Clinical Research Training in Hematology (CRTH) programs, offered to junior hematology researchers and physicians. Speaking from the American Society of Hematology (ASH) Annual Meeting 2017 in Atlanta, GA, Felicitas Thol, MD, of Hannover Medical School, Hannover, Germany, describes her experience of the TRTH program. Provided by the European Hematology Association (EHA) and ASH, TRTH aims to promote the careers of young physicians and researchers in hematology. Dr Thol also explains how the CRTH program, offered by the EHA, teaches junior researchers the skills needed…

It is extremely important to assess the long-term effects of chemotherapy in patients with acute myeloid leukemia (AML); however, with the knowledge of minimal residual disease, it is understood that not all malignant clones can be seen under the microscope. In this interview, Felicitas Thol, MD, of Hannover Medical School, Hannover, Germany, discusses the importance of using novel techniques when observing remission in patients. Although challenging compared to other diseases, such as chronic myeloid leukemia (CML), Dr Thol suggests a more individualized and sensitive approach should be taken due to the complex nature of AML. This interview was held at…

Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group at the 2018 ASCO.

Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy at the 2018 ASCO.

Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements at the 2018 ASCO.

Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients at the 2018 ASCO.

Only one treatment for malignant mesothelioma has been approved since 2003 and rates of the disease are rising worldwide; thus, new treatments must be found. Here, Dean Fennell, PhD, FRCP, of University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the late phase randomized trials that he is excited about. Prof. Dean highlights CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM; NCT03063450) which is investigating nivolumab; the PROMISE-meso study (NCT02991482) of pembrolizumab vs. standard chemotherapy; and the VIM trial (NCT02139904) of vinorelbine in the second-line setting. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018,…

There is currently an array of exciting clinical trials for mesothelioma, investigating cutting-edge treatments in large patient groups. Here, Dean Fennell, PhD, FRCP, of University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the key mesothelioma trials that the UK is running or taking part in. Prof. Fennell covers the Phase III CheckMate 743 trial (NCT02899299) of double immunotherapy (nivolumab and ipilimumab) in the frontline setting; the Phase II/III global ATOMIC trial (NCT02709512) of ADI-PEG 20 for patients with malignant pleural mesothelioma (MPM); and the international umbrella study of Mesothelioma Stratified Therapy (MiST) for MPM, which will be the first…

There has been a vast increase in our understanding of the pathology of mesothelioma in the past 5 years, which is hoped to revolutionize the treatment of the disease, whose incidence is rising globally. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Dean Fennell, PhD, FRCP, of University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the genes involved in the development of mesothelioma and the studies investigating treatments to target them. Prof. Fennel emphasizes the role of BAP1 and BRCA1 in homologous recombination; the common CDKN2A (p16) deletion; and novel immunotherapy combinations…

Mesothelioma cases are on the rise, in both developed and developing countries. Thus, increased understanding of the underlying mechanisms of the disease is essential. Here, Dean Fennell, PhD, FRCP, of University Hospitals of Leicester NHS Trust, Leicester, UK, explains what he believes the key unanswered question in mesothelioma is. Prof. Fennel highlights the need to identify genetic vulnerabilities, equivalent to those provided by EGFR or ALK in lung cancer, to enable the precise targeting of the disease. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

The first study illustrating the potential of MRI in the diagnosis of prostate cancer was published in 2006. Although there have since been a number of other studies showing this utility, the use of MRI in this field is still debated. Here, Mark Emberton, MD, FRCS, of University College London, London, UK, discusses the debate he took part in on this topic at the 2018 Genitourinary Cancers Symposium, in San Francisco, CA. Speaking from the meeting, Prof. Emberton discusses the results of randomized clinical trials, which he presented to support his case for this technology, including the the PROstate Mri…

The current diagnostic methods for prostate cancer are not always as reliable or accurate as they could be, leading to mis- or over-diagnosis, and thus the treatment of patients who will not benefit from it. In this interesting interview, Mark Emberton, MD, FRCS, of University College London, London, UK, discusses the key challenge in this area: effective risk stratification. Prof. Emberton highlights the need in this area, touching upon trials of promising drugs and comparing them to similar therapeutics that have been studied in breast cancer. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco,…

Recent news reports have identified poorer outcomes in cancer patients from the UK compared with those in certain other European countries. Here, Mark Emberton, MD, FRCS, of University College London, London, UK, discusses the most commonly speculated reason for this: delayed diagnosis. Prof. Emberton postulates on the reasons for this delayed diagnosis and disucsses how the UK is addressing the issue. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

The take-home message from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, on MRI for prostate cancer diagnosis was positive. However, this leaves us with a variety of questions. In this interview, filmed at the meeting, Mark Emberton, MD, FRCS, of University College London, London, UK, gives us a concise and comprehensive summary of the economic and logistical issues with the use of MRI for prostate cancer diagnosis, including accessibility and changes to the previously straightforward diagnostic pathway.

The utilization of MRI for the diagnosis of prostate cancer in men at risk is relatively new. In this interview, filmed at the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, Mark Emberton, MD, FRCS, of University College London, London, UK, explains why the use of MRI is important for the diagnosis and treatment of prostate cancer. Prof. Emberton also explains the problems that can arise from not determining tumor location and volume at diagnosis.

Current practice in the UK requires urologists to refer patients with urological cancer to oncologists for treatment. In this interview, Mark Emberton, MD, FRCS, of University College London, London, UK, gives us an insight into the dynamics of a team responsible for the management of a patient with urological cancer in the UK. Prof. Emberton highlights the essential roles of different team members, who offer their own unique sets of expertise. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

Highly anticipated data from the Phase III SPARTAN study (NCT01946204), which investigated apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC), was presented at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA. In this interesting interview from the meeting, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the results of the trial. Dr Small highlights the excellent primary and secondary endpoint data, including risk reduction and time to metastasis, as well as results for toxicity. In addition, he covers the doubled-blinded aspect of the study design and how this affected access to…

There has previously been no effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC). Now there are several exciting late-phase clinical trials investigating promising treatments for nmCRPC, which are likely to be in the clinic soon. In this interview, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides an overview of the Phase III double-blind SPARTAN trial (NCT01946204), which tested apalutamide in this group. Dr Small explains the straightforward design of the study, including the inclusion criteria. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

With exciting data from the Phase III SPARTAN (NCT01946204) and PROSPER (NCT02003924) trials of apalutamide and enzalutamide, respectively, for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC), a question arising is which drug is better. Speaking from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses this question.

The emergence of an effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is likely to have a paradigm-changing effect on the treatment of CRPC. In this informative talk with Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, he discusses how he expects that the results of the SPARTAN trial (NCT01946204) of apalutamide will impact clinical practice in the US. Dr Small highlights the identification of patients at high-risk of progression, the benefits of early treatment and the effect of this treatment on later therapy. He also discusses the questions that are yet to…

Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a disease which had no FDA-approved treatment. Following the completion of the Phase III SPARTAN trial (NCT01946204), a new nonsteroidal antiandrogen (NSAA) treatment, apalutamide, is showing promise in this area. In this exciting interview, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses how the encouraging results of this study will impact the treatment and outcomes of patients with nmCRPC. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

With the emergence of five novel immune checkpoint inhibitors for the treatment of urothelial carcinoma, the key question now arising is how to identify the subgroups of patients who will benefit from this therapy. As discussed here by Thomas Powles, MD, of Barts Cancer Institute, London, UK, PD-L1 expression is the primary biomarker used. However, Prof. Powles points to a second-generation of biomarkers emerging, including RNA expression, tumor mutational burden (TMB) and TGF-?. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

A highly anticipated topic at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, was immune checkpoint inhibitor data for bladder cancer. Here, Thomas Powles, MD, of Barts Cancer Institute, London, UK, tells us about the Phase III IMvigor211 study (NCT02302807), which is investigating the use of atezolizumab vs. standard chemotherapy in bladder cancer patients who have relapsed following platinum-based chemotherapy. Prof. Powles highlights the PD-L1 biomarker detection used in this trial and the unexpected results from this, followed by the interesting further analysis, including that of tumor mutational burden (TMB).

Immune checkpoint inhibitors for urothelial carcinoma in the relapsed/refractory setting have already been approved and are superseding standard chemotherapy. Now, there are exciting late-phase clinical trials investigating their use in the frontline setting. Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Thomas Powles, MD, of Barts Cancer Institute, London, UK, discusses whether checkpoint inhibitors could replace platinum-based chemotherapy as the new standard of care for urothelial cancer in all settings. Prof. Powles speculates on their use, either in combination with chemotherapy or other immunotherapeutics. He also discusses the further questions that need to be answered, including…

Novel immune checkpoint inhibitors that are entering the clinic are changing the way in which we treat metastatic urothelial carcinoma, the most common type of bladder cancer. In this interview, Thomas Powles, MD, of Barts Cancer Institute, London, UK, gives us an overview of the use of these agents in patients who have failed platinum-based chemotherapy, as well as previously untreated patients. Prof. Powles discussing the promising agents, how they stack up against standard chemotherapy and key trials in this area. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

Minimal residual disease (MRD) monitoring is a promising and controversial topic, with its increasing use in clinical trials being followed acutely. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, highlights studies of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) which are monitoring MRD.

There was exciting new trial data for the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the current management and role of stem cell transplantation in this malignancy, in both the pediatric and elderly settings.

Older acute myeloid leukemia (AML) patients are not typically given intensive cytotoxic chemotherapy due to their fragility and comorbidities. Decitabine has previously been demonstrated to improve survival rates in this population, but the optimal dosing schedule is not well established. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the randomized Phase II trial (NCT01786343) comparing 5-day vs. 10-day dosing regimens of decitabine in older treatment-naïve AML patients. Dr Ravandi also discusses the possible explanations…

The outcomes of patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) are poor, with no standard therapy. In this interview, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the Phase I/II study (NCT02257138) of ruxolitinib plus decitabine in patients with post-MPN AML. He emphasizes that the interim results have demonstrated promising response rates in this subpopulation of patients, but will need further investigation to assess its safety and efficacy. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the pilot Phase II study (NCT02464657) of cytarabine, idarubicin and the PD-1 inhibitor nivolumab for young patients with newly diagnosed acute myeloid leukemia (AML). Dr Ravandi highlights the early data, including response rates and follow-up data, suggesting that this therapeutic approach is feasible and warrants further evaluation in future studies. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, was an exciting one for multiple myeloma (MM) data. In this interesting interview, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, speaking from the meeting, discusses the highlights for MM. With an emphasis on data from the UK, Prof. Jackson highlights the results of specific trials, including Myeloma XI (NCT01554852), and the inclusion of patients with a poorer performance status in these trials.

Minimal residual disease (MRD) is the major cause of relapse in multiple myeloma (MM), and measurements of its level can be utilized to determine treatment response and prognosis. Here, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, discusses the impact of MRD status and cytogenetics on the treatment response of MM patients in the Phase III Myeloma XI trial (NCT01554852), which investigated the benefit of lenalidomide maintence therapy. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

At the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, was selected to present data from the Phase III Myeloma XI trial (NCT01554852) in the oral session. This large-scale exciting trial evaluated the use of lenalidomide maintenance therapy for newly-diagnosed multiple myeloma (MM) patients, who were eligible or ineligible for stem cell transplantation. In this interview, speaking from the meeting, Prof. Jackson provides an overview of the study, its key findings and what they mean.

Copanlisib is a novel PI3K inhibitor, targeting both PI3K-? and PI3K-? isoforms in malignant B-cells. It was granted FDA approval based on data from the Phase II CHRONOS-1 study (NCT01660451) investigating copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the longer term follow-up data being presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Ibrutinib combination therapy in an exciting therapeutic area with great potential. Many recent and ongoing studies are seeking to identify the optimal ibrutinib combinations for the treatment of chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, highlights data that was presented at the meeting which evaluated ibrutinib combination therapy for CLL, including that with venetoclax and anti-CD20 antibodies.

Data from the Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, provides an update on this study and how he anticipates the results will change the treatment of CLL.

Treating lymphoma patients in the relapsed/refractory setting often proves a challenge for physicians. PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is a chemotherapy regimen used with palliative intent in these patients. Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the retrospective study of PEP-C use in relapsed/refractory lymphoma patients over an 8-year period. The data will allow for physicians to use this utilize this regimen and improve patients quality of life during the end-of-life phase. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in…

In the UK, escalated BEACOPP (escBEACOPP) was introduced as an alternative to ABVD for the treatment of advanced-stage Hodgkin lymphoma (HL). Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the 10-year retrospective study of ABVD vs. escBEACOPP in HL patients in both trial (RATHL; Trial: RATHL, NCT00678327) and non-trial settings. Dr Follows expresses excitement at presenting the data at this years American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

An exciting new nurse-led rapid access lung cancer clinic has been started in Ceredigion, Wales. Here, the Clinical Nurse Specialist leading the clinic, Sarah Morgan, of Hywel Dda University Health Board, Carmarthen, UK, gives us an overview of the clinic, including the services it provides, and the process of seeing and evaluating patients. She also highlights why the clinic is particularly important for the area and how it differs from other clinics. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

This years British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, presented a range of exciting data, with talks on a National Optimal Lung Cancer Pathway (NOLCP) for the UK a hot topic. Speaking from the meeting, Sarah Morgan, of Hywel Dda University Health Board, Carmarthen, UK, gives us her high points from the meeting. She highlights information on the NOLCP, commenting on lung cancer care in Wales, as well as the collaborative research which the meeting fosters.

The role of the nurse in the management and care of patients with cancer is essential one, which is evolving both nationally and internationally. One example of this expanding role is the creation of nurse-led cancer clinics. In this interview, Clinical Nurse Specialist Sarah Morgan, of Hywel Dda University Health Board, Carmarthen, UK, discusses the nurse-led rapid access lung cancer clinic she recently set up in Ceredigion, Wales. Sarah discusses the positive feedback from patients so far, highlighting the support, education and continuity they can receive throughout the cancer pathway. She also discusses future steps for the project, including evaluation,…

Robotic surgery equipment is notoriously expensive, limiting the number of hospitals and surgeons who can utilize this beneficial technology. In this interview, Joel Dunning, PhD, FRCS, of South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK, gives us a practical demonstration of an innovative piece of tech, which is aiming to bring robotic-assisted surgery to the masses. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Where there was previously one primary manufacturer for robotic-assisted surgery machinery, there are now several newcomers on the block. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Joel Dunning, PhD, FRCS, of South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK, discusses the new robotic surgery platforms on the horizon, with major companies competing. Dr Dunning also forecasts where he sees the future of thoracic surgery moving in terms of the relationship between robotic-assisted surgery and video-assisted thoracoscopic surgery (VATS).

Despite some forms of minimally invasive surgery being performed for some time, we are still lacking the analytical evidence that endoscopic thoracic surgery is better than that through a thoracotomy. In this interview, Joel Dunning, PhD, FRCS, of South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK, discuses the ongoing VIOLET study (ISRCTN13472721), a large multicenter randomized controlled trial of video-assisted thoracoscopic surgery (VATS) vs. open lobectomy for lung cancer. Dr Dunning also discusses why we might have a lack of data for robotic-assisted thoracic surgery. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held…

Robotic-assisted thoracic surgery can be combined with other techniques and utilized for a wide range of procedures. Here, Joel Dunning, PhD, FRCS, of South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK, gives us a run-down on the procedures robotics can be used in during thoracic surgery and the benefits of this technique. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Robotic-assisted surgery is an exciting, innovative area, which is growing and becoming more widespread. Here, Joel Dunning, PhD, FRCS, of South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK, gives us an interesting overview of robotic-assisted thoracic surgery, debunking some common misconceptions. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

This is an exciting time for chronic lymphocytic leukemia (CLL) research, with the possibility of chemotherapy-free treatment approaches. In this interview, Florence Cymbalista, MD, of Avicenne Hospital, Bobigny, France, discusses the Phase II study of obinutuzumab plus ibrutinib, followed by a chemo-sparing strategy, in treatment-naïve CLL patients (ICLL07GAI; NCT02666898). The preliminary results are encouraging, with the full dataset highlight anticipated at next year’s meeting. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Little is known about TP53 mutations and their association with adverse prognosis and chemotherapy resistance in chronic lymphocytic leukemia (CLL). Here, Florence Cymbalista, MD, of Avicenne Hospital, Bobigny, France, discusses the retrospective analysis of CLL patients with TP3 mutations from the French Innovative Leukemia Organization (FILO) Group. She highlights the need for further investigation and the importance of databases of genetic mutations. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,

Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Immune & Combination Therapies Will be Important for Years Because of tougher, older, and resistant patient populations at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Adverse Effects of Venetoclax and Ibrutinib Only 1 in 50 Patients had Tumor Lysis Syndrome at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about Drugs to Use if One has Cancer or Clots Rivaroxaban, Apixaban, Edoxaban are effective oral drugs at MOASCs Spotlight On® Hematology in Huntington Beach.

Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses CLARITY Trial Limitations; No Control Group Extrapolated onto the FLAIR Trial Studying Group Combinations at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks Diagnostic Criteria for Thrombotic Thrombocytopenic Purpura One needs less than 10 of ADAMTS13 activity at MOASCs Spotlight On® Hematology in Huntington Beach.

Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Positive Data for RR-CLL Patients Able to see MRD Negativity at month 6 at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks Highlights from MDS and Nonmalignant Hematology New drugs for MDS: Rigosertib, Luspatercept, Ibrutnib at MOASCs Spotlight On® Hematology in Huntington Beach.

Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses The CLARITY Trial Lead by Dr. Hillmen Feasibility study that looked at efficacy of Ibrutnib and Venetolax in RR-CLL at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Angela Fleischman MD PhD UC Irvine discusses JAK Inhibitors are a Central Theme in MPN Lots of JAK Inhibitors being tested in clinical trials at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Elizabeth Br̩m, MD РHS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Rituximab Maintenance for Follicular Lymphoma CAR-T Trial salvages Primary, Refractory, or those who failed initial therapyat MOASCs Spotlight On Hematology in Huntington Beach 2018.

Angela Fleischman MD PhD UC Irvine discusses Disease Managing Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations associated with Myeloid Malignancies; DNMT3A, TET2, JACK2-V617F at MOASCs Spotlight On Hematology in Huntington Beach 2018.         clonal hematopoiesis, indeterminate potential (CHIP) mutations, myeloid malignancies, dnmt3a, tet2, jack2-v617f, moasc spotlight, hematology

Elizabeth Br̩m, MD РHS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Echelon-1 Data Showed Modified Progression Free Survival Increased toxicity may not be worth a few points in overall survival at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Angela Fleischman MD PhD UC Irvine discusses Distinguishing Between Clonal Disorder & a Germ-Line Mutation Clonal disorder is a hematologic malignancy; risk of Myelofibrosis at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Elizabeth Br̩m, MD РHS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Angela Fleischman MD PhD UC Irvine discusses Preventing Progress of MPN Presently this area is limited and needs to be focused on at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Elizabeth Br̩m, MD РHS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses updates on PRIMA Study Progression Free Survival from patients with Rituximab Maintenance at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Angela Fleischman MD PhD UC Irvine discusses MPN (Myeloproliferative Neoplasm) & CHIP New phenomenon in aging individuals with mutations associated with MM at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Elizabeth Br̩m, MD РHS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses how CAR-T Therapies will Dominate in 2018 Next Generation BTK Inhibitor data is still early at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Angela Fleischman MD PhD UC Irvine discusses Disease Modifying Agents on the Horizon for MPN Hope to impact, intervene, & change course of disease progression early at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Elizabeth Br̩m, MD РHS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses updates Retrospective Analysis Looked At Rituximab Maintenance Patients achieving partial remission benefited most from rituximab maintenance at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical role cellular functions, including modulation of growth factor signaling, proliferation, carcinogenesis, and cell differentiation. Several TKIs, including sorafenib and regorafenib, have already been approved for first and second line treatment of hepatocellular carcinoma (HCC), respectively. Further, a plethora of novel TKIs such as lenvatinib and cabozantinib are being investigated for their potential use in the therapeutic management of HCC. In this whiteboard video, Dr. Richard S. Finn of the UCLA Geffen School of Medicine discusses the management of adverse events…

Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical role cellular functions, including modulation of growth factor signaling, proliferation, carcinogenesis, and cell differentiation. Several TKIs, including sorafenib and regorafenib, have already been approved for first and second line treatment of hepatocellular carcinoma (HCC), respectively. Further, a plethora of novel TKIs such as lenvatinib and cabozantinib are being investigated for their potential use in the therapeutic management of HCC. In this whiteboard video, Dr. Richard S. Finn of the UCLA Geffen School of Medicine describes the role of TKIs in…

Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical role cellular functions, including modulation of growth factor signaling, proliferation, carcinogenesis, and cell differentiation. Several TKIs, including sorafenib and regorafenib, have already been approved for first and second line treatment of hepatocellular carcinoma (HCC), respectively. Further, a plethora of novel TKIs such as lenvatinib and cabozantinib are being investigated for their potential use in the therapeutic management of HCC. In this whiteboard video, Dr. Richard S. Finn of the UCLA Geffen School of Medicine outlines the epidemiology and current standard…

In this Velocity Vlog activity, Dr. Richard S. Finn of the UCLA Geffen School of Medicine, provides a brief overview of the epidemiology of hepatocellular carcinoma and then discusses current standards of care and clinical trial updates presented during the American Society of Clinical Oncology’s 2018 Gastrointestinal Cancers Symposium in San Francisco. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7285 © 2018 Imedex, LLC.

Filanesib is a novel agent that has previously shown clinical activity in pretreated multiple myeloma (MM) patients. In this interview, Enrique Ocio, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, gives us an overview of the Phase Ib/II trial (NCT02384083), which evaluated filanesib in combination with pomalidomide and dexamethasone in relapsed/refractory MM. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Enrique Ocio, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, gives us an overview of the GEM-Pembresid trial (NCT02636010), which evaluated pembrolizumab as a consolidation therapy in multiple myeloma (MM). He discusses the findings from initial data and its potential clinical implications. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

VCD (bortezomib, cyclophosphamide and dexamethasone) is an effective chemotherapy combination commonly used for the treatment of newly diagnosed multiple myeloma (MM), while bortezomib combined with isatuximab has shown potential in MM xenograft models. Thus, the combination of isatuximab with VCD (VCDI) is a promising one. Here, Enrique Ocio, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, provides an update on the Phase Ib study (NCT02513186) of VCDI in newly diagnosed MM patients who are ineligible for transplantation. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, he discusses the promising results of…

The results of the Phase III MURANO trial (NCT02005471) were important to address a number of unanswered questions surrounding the use of venetoclax. Here, Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discusses the first results of theMURANO study of venetoclax plus rituximab vs. bendamustine plus rituximab for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). Prof. Kater highlights the promising results, which demonstrate that this combination has the potential to provide an important new chemotherapy-free option for patients with previously treated CLL. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting…

Now that hematological oncologists have an arsenal of novel single agents, the natural next step is to determine the best combinations of these agetns, both with one another and with standard chemotherapeutics. In this interview, Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discusses advancements in chronic lymphocytic leukemia (CLL) therapy, particularly novel combinations, which have shown clinical promise. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,

With the increasing use of immunotherapy, methods of response testing need to be rigorous and comparable. However, as explained here by Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, the current response assays used differ both between drugs and in cut-off scores. Prof. Hirsch discusses the Blueprint PD-L1 IHC Assay Comparison Project, which aims to provide information on the analytical and clinical comparability of four PD-L1 IHC assays used in clinical trials. He covers the Phase I and II results and conclusions, and the next steps for the project. This video was recorded at the British Thoracic Oncology…

There are many areas of uncertainty surround immunotherapy, which require further exploration in the coming years. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, discusses some of the most pertinent issues, including resistance mechanisms and the sequencing of therapies. Prof. Hirsch also highlights the need for the further study of immunotherapy in the locoregional and localized settings.

Now that there is a range of immunotherapies available, the next frontier to explore is immunotherapy combination regimens. In this interview, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, discusses the optimal immunotherapy combinations for lung cancer, referencing recent or ongoing clinical trial data. Prof. Hirsch highlights results from the combination of pembrolizumab with chemotherapy in the Phase II KEYNOTE-021 (NCT02039674) and Phase III KEYNOTE-189 (NCT02578680) studies for non-small cell lung cancer (NSCLC). He also discusses immunotherapy plus immunotherapy combinations, such as that investigated in the CheckMate 032 trial (NCT01928394), of nivolumab plus ipilimumab for small cell lung…

At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, gave a very interesting talk on predictive response assays for lung cancer immunotherapy. Speaking from the meeting, Prof. Hirsch highlights the take-home points of his talk, raising thought-provoking questions for further consideration. These questions include: Are all mutations immunogenically equal? Should we combine PDL-1 and TMB assays? Should alternative markers, such as CTLA4 mRNA, be used? What other aspects of immune escape need to be considered?

Tumor mutational burden (TMB) is emerging as a promising predictive biomarker for lung cancer immunotherapy response. Here, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, discusses the data available on this method so far and the further analysis that he thinks is needed, in terms of both evaluation and the complex issue of assay standardization. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

With the great promise that immunotherapy holds, there are hopes that it will revolutionize the treatment of lung cancer. Here, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, discusses whether, by combining and personalizing immunotherapy, we could reach a point where we can curatively treat advanced non-small cell lung cancer (NSCLC). This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

With exciting data for immuno-oncology in lung cancer, there is much anticipation for what 2018 holds. In this interview, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, updates us on the immunotherapy trial data to look out for in 2018. Prof. Peters also discusses what she hopes the European Society of Medical Oncology (ESMO) 2018 Congress later in the year will have on the agenda in this field. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Immunotherapy is an exciting area for lung cancer, with numerous possibilities and game-changing potential. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, discusses the future of immunotherapy for non-small cell lung cancer (NSCLC). Prof. Peters highlights the recent Phase III PACIFIC trial (NCT02125461) of durvalumab, which produced outstanding progression-free survival results. She then emphasizes what immunotherapy developments she is most excited about.

After many negative trial results for non-small cell lung cancer (NSCLC) therapies for some time, the field is now evolving in a very promising direction fast. Here, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, discusses the role of immunotherapy in the radical treatment of NSCLC, following the recent publication of data from the Phase III PACIFIC study (NCT02125461) of durvalumab. Prof. Peters highlights the many combination options for immunotherapy, including that with radiotherapy. She also covers the role of chemotherapy and surgery in the context of immunotherapy. This video was recorded at the British Thoracic Oncology Group…

Numerous trials worldwide are now focusing on combination therapy for relapsed/refractory chronic lymphocytic leukemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, discusses the take-home messages from data for combination therapy for CLL presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Data from the Phase III MURANO study (NCT02005471) is a hot topic in the field of hematological oncology. The study evaluated the use of venetoclax plus rituximab vs. standard chemoimmunotherapy (bendamustine plus rituximab) in relapsed/refractory chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, provides an overview of the study and forecasts how she sees the results of this trial shaping CLL treatment moving forwards.

Sequential triple-T therapy is a regimen consisting of tailored and targeted treatment aiming for total eradication of minimal residual disease (MRD). Here, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, provides an overview of the Phase II CLL2-BIO study (NCT02689141) of bendamustine, ofatumumab and ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL) patients. Dr Eichhorst highlights the promising results of this sequential regimen. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Fludarabine, cyclophosphamide and rituximab (FCR) is the standard chemotherapy regimen used to treat chronic lymphocytic leukaemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, provides an overview of the Phase III CLL10 study (NCT00769522), which compared the efficacy and tolerance of FCR vs. bendamustine in combination with rituximab. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Over the past 10 years, there has been a massive expansion in the number and classes of treatments available for myeloid malignancies. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Dr Amir Fathi, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides insight into the exciting areas of advancement in acute myeloid leukaemia (AML). He highlights clinical trials evaluating IDH and FLT3 inhibitors, antibody-drug conjugates, and liposomal formulations of traditional chemotherapeutic drugs, all of which have demonstrated various extents of clinical promise.

The last 5-10 years has been a very exciting time for the treatment of myeloid malignancies, with great advances in targeted therapies. Amir Fathi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses therapy targeting isocitrate dehydrogenase (IDH) in acute myeloid leukaemia (AML). Dr Fathi highlights studies which hare evaluating IDH inhibitors as a monotherapy or in combination with other types of treatment, for which the preliminary data is promising. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Presented by Robert Z. Orlowski, MD, PhD; and Peter M. Voorhees, MD. Part 1 of 3 of a symposium recorded at an oncology specialty meeting.

Presented by Ajay K. Nooka, MD, MPH, FACP. Part 2 of 3 of a symposium recorded at an oncology specialty meeting.

Presented by Ajay K. Nooka, MD, MPH, FACP; Robert Z. Orlowski, MD, PhD; and Peter M. Voorhees, MD. Part 3 of 3 of a symposium recorded at an oncology specialty meeting.

Data for non-chemotherapy-based treatments is increasing exponentially, with the presentations at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, proving no exception to this trend. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the most promising therapeutic areas in chronic lymphocytic leukemia (CLL) from the meeting. He expresses excitement at the long-term follow-up data for ibrutinib and acalabrutinib, as well as expanding roles for 2nd generation kinase inhibitors and combinations utilizing venetoclax.

Immune checkpoint inhibitors and T-cell engaging bi-specific antibodies have shown promising activity against lymphoid malignancies. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the open-label, multicenter study of REGN2810 alone or in combination with REGN1979 in patients with B-lymphoid malignancies (NCT02651662). This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Data from recent studies indicate that PD-1 and PD-L1/PD-L2 mediate immune evasion in chronic lymphocytic leukemia (CLL), highlighting their importance in this malignancy. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the Phase I/II study of pembrolizumab in combination with ublituximab and umbralisib in patients with relapsed/refractory CLL (NCT02535286). Notably, this was the first ever study of PI3K-? inhibiton in combination with anti-PD-1 therapy in CLL patients. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about updates on Myelodysplastic syndrome and nonmalignant hemetology at MOASCs Spotlight On® Hematology in Huntington Beach.

Angela Fleischman, MD, from UC Irvine joins us at MOASCs Spotlight On Hematology in Huntington Beach to discusses the updates in myeloproliferative neoplasm, abstracts from ASH 2017 and papers that are important for the understanding of myeloproliferative neoplasms.

Deepa Jeyakumar, MD, from UC Irvine Health discusses the Acute myeloid leukemia highlights from ASH 2017 at MOASCs Spotlight On® Hematology in Huntington Beach.

Elizabeth Brém, MD, from The Chao Comprehensive Cancer Center joins us at MOASCs Spotlight On® Hematology in Huntington Beach to present some of the highlights of ASH 2017 Lymphomas.

Amrita Krishnan MD FACP of The Judy and Bernard Briskin Center for Multiple Myeloma Research discusses the updates at ASH 2017 of the treatment of multiple myeloma at the 2018 MOASC Spotlight on Hematology meeting in Huntington Beach, CA.

Ann Eapen, MD, from UC-Irvine Department of Hematology and Oncology is presenting the CLARITY Trial (Bloodwise TAP Study) which looks at the high rates of overall response, complete remission, and MRD eradication after 6 months of combination therapy at the MOASCs “Spotlight On: Hematology” in Huntington Beach.

Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach to present “Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic lymphocytic leukemia.”

Deepa Jeyakumar, MD, from UC Irvine Health talks about trying to understand the role of CPX-351 and if can be used as an outpatient for newly-diagnosed AML at MOASCs Spotlight On® Hematology in Huntington Beach.

Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach to talk about the safety of chronic lymphocytic leukemia combination therapy and the fair number of hematologic & non-hematologic adverse effects.

Deepa Jeyakumar, MD, from UC Irvine Health For Multiple Myeloma Research joins us at MOASCs Spotlight On® Hematology in Huntington Beach to discuss the toxicities with IDH1 & IDH2 inhibitors and a new side-effect the IDH differentiation syndrome.

Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On® Hematology in Huntington Beach to discuss different strategies for treating relapsed myeloma including Daratumumab with IMiDs, Venetoclax, and transplants.

Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach to discuss the trials in combination therapy for Chronic Lymphocytic Leukemia and the phase 2 trial results with Obinutuzumab, Ibrutunib, & Venetoclax in conjunction.

Deepa Jeyakumar, MD, from UC Irvine Health talks about, Midostaurin, the 1st new and approved AML drug in a long time for patients with FLT3 positive AML in the upfront setting at MOASCs Spotlight On® Hematology in Huntington Beach.

Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On® Hematology in Huntington Beach to talk about the tandem transplantation in multiple myeloma and a Phase 3 trial showed patients had a progression free survival benefit.

Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center joins us at MOASCs Spotlight On® Hematology in Huntington Beach to discuss the effective oral drugs to use (Rivaroxaban, Apixaban, Edoxaban) if one has cancer or clots.

Deepa Jeyakumar, MD, from UC Irvine Health discusses how IDH2 inhibitor for AML is effective with Relapsed Refractory disease and the differentiation syndrome is a worrying side-effect all at MOASCs Spotlight On® Hematology in Huntington Beach.

Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On® Hematology in Huntington Beach to talk about the Bluebird trial BCMA CAR-T on 24 patients and over half of patients getting complete remissions.

Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about the diagnostic criteria for thrombotic thrombocytopenic purpura and how one needs less than 10% of ADAMTS13 activity at MOASCs Spotlight On® Hematology in Huntington Beach.

Deepa Jeyakumar, MD, from UC Irvine Health talks about 4 new drugs for acute myeloid leukemia including Midostaurin, Gemtuzumab, and updates in CPX-351 at MOASCs Spotlight On® Hematology in Huntington Beach.

Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research talks about the antibody drug conjugate against BCMA – 60% response rate in refractory myeloma at MOASCs Spotlight On® Hematology in Huntington Beach.

Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about the highlights from Myelodysplastic Syndrome (MDS) and nonmalignant hematology and also new drugs for MDS: Rigosertib, Luspatercept, Ibrutnib at MOASCs Spotlight On® Hematology in Huntington Beach.

Venetoclax is approved for the treatment of relapsed/refractory del17p chronic lymphocytic leukemia (CLL) and has shown activity in patients following the failure of kinase inhibitors. However, there is a lack of data availlable for outcomes, toxicities and the dose ramp-up period in the real world, as well as treatment selection following discontinuation. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the results of a retrospective study analyzing the largest cohort of venetoclax-treated patients to date, from across almost 20 US and international academic and community centers. This interview was recorded at the American…

Ibrutinib is approved for all lines of therapy in chronic lymphocytic leukemia (CLL); however, front-line ibrutinib studies have primarily enrolled older low-risk patients, which are not representative of all patients seen in the clinic. Here, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses a multicenter retrospective study he is involved with evaluating the front-line use of ibrutinib in CLL patients treated in a real-world setting, focusing on adverse events, discontinuations, outcomes and subsequent therapies. Dr Mato highlights the encouraging results and need for trials studying the best treatment strategy post-ibrutinib. This interview was recorded at the…

The rapidly changing landscape of NSCLC treatment has drastically improved outcomes for patients. In this interview, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP of The Christie NHS Foundation Trust, Manchester, UK discusses targeted medicine for NSCLC patients with ALK gene rearrangements. Dr Summers provides an overview of the impact of the PROFILE 1014 trial (NCT01154140), which tested the efficacy of crizotinib in this patient group. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.

Knowledge about the different subtypes of and mutations within NSCLC has increased dramatically in the past 10 years. Here, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from The Christie NHS Foundation Trust, Manchester, UK discusses changes in the diagnosis and treatment of NSCLC as a result of this increased understanding. Key areas covered include resistance to EGFR TKIs, such as that caused by the T790M mutation, and repeat biopsies and whether ctDNA could be used as an alternative or complementary method of mutation identification. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017…

Integrated healthcare is vital to provide the optimal care to cancer patients at all stages, from diagnosis to remission and beyond. In this interview, Trisha Hatt from Macmillan Cancer Support, Glasgow, UK, discusses the Improving the Cancer Journey service in Glasgow, which takes a multi-partnership approach to work across the boundaries of acute, community and primary care. Ms Hatt provides an update on the outcomes and highlights the importance of pharmacists in this care model. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.

Beating cancer takes more than good luck and a good doctor, a high-tech medical center and exotic drugs. It takes a savvy patient capable of enduring the unexpected and making critical decisions under stress. That is precisely when God wants to speak into your life and what a difference that makes for those who pursue Him!

Only one TKI is approved in a first line setting. Joining us from the 2018 Gastrointestinal Cancers Symposium is Dr. Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, describes the different TKI’s and their uses and also the status of sequencing them.

Dr. Khaldoun Almhanna, MD, MPH, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, talks about the current state of gastroesophageal cancer screening and describes its use within the United States, here at the 2018 Gastrointestinal Cancers Symposium.

The AJCC guidelines have incorporated several new features, Kenneth Wang, MD, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, explains these several new features like the separation on early stage cancer and a new criteria added to the system at the 2018 Gastrointestinal Cancers Symposium.

The exciting 100,000 Genomes Project has the potential to transform the way patients are cared for. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Anna Schuh, MD, PhD, from the University of Oxford, UK, discusses the main aims of the project, including access to genetic testing, identification of therapy response markers and database creation. Prof. Schuh emphasizes the wide-reaching impacts of the project, transforming the UK genomics industry.

Stivarga (regorafenib) is an effective drug but not one that is easily tolerable. Howard Hochster, MD, talks to us about the ReDOS study and its outcomes at the 2018 Gastrointestinal Cancers Symposium.

The 100,000 Genomes Project is an exciting NHS programme, which aims to sequence 100,000 genomes from patients with rare diseases and their families, as well as patients with cancer. In this interview, Anna Schuh, MD, PhD, from the University of Oxford, UK, provides an update on the intriguing project, which has the potential to transform genomic medicine services. Prof. Schuh covers recruitment progress, optimizing germline control samples and plans for 2018.This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Bloodwise’s Trials Acceleration Programme (TAP) aims to boost the number and speed of hematological oncology studies in the UK. Here, Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, summarizes the latest results of the TAP CLARITY study (ISCRTN13751862), which assessed the use of venetoclax in combination with ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Prof. Schuh emphasizes the exciting objective response and MRD rates at 8 months, and discusses the plans for continuation to a Phase III trial. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

While single agents are able to control relapsed chronic lymphocytic leukemia (CLL) well, they do not provide a cure. In this interview, Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, discusses recent data regarding the use of combination therapy for the treatment of relapsed CLL, such as venetoclax with ibrutinib or antibody therapy. Prof. Schuh highlights the promising results of the CLARITY study (ISRCTN13751862) of ibrutinib in combination with venetoclax, which produced impressive MRD negativity rates. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

The issue of smoking and lung cancer screening poses many questions. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Neal Navani, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses the issue, referencing data from the US National Lung Screening Trial (NLST; NCT00047385) and the UK Lung Cancer Screening pilot trial (UKLS; ISRCTN78513845).

It widely agreed that we need to identify better methods of detecting lung earlier. There has been great data suggesting the use of low-dose CT scans for screening. However, can the benefits of this screening be carried over into the clinic? Here, Neal Navani, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses the issue, including whether many countries will have the healthcare resources required. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Reducing the length of diagnostic pathways can increase the number treatment options available and enable better patient experiences. Here, Neal Navani, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses exciting data in this area from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Prior to the evaluation of whether lung cancer screening should be adopted, its impact on patient survival must be thoroughly investigated. In this topical interview, Neal Navani, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses the US National Lung Screening Trial (NLST; NCT00047385) and the European NELSON trial (ISRCTN63545820), for which further results are expected in late 2018. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

The early detection of lung cancer is an exciting field with the potential to greatly improve patient survival. Currently, the topic of screening dominates the agenda in this area, and several countries have already begun to implement screening. Here, Neal Navani, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses whether the UK will follow suit. Dr Navani also highlights the need to consider smoking cessation programmes within screening. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

The National Optimal Lung Cancer Pathway (NOLCP) was a much-discussed topic at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland. Speaking from the meeting, Neal Navani, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses the implementation of this pathway, including timelines, investment and infrastructure.

Long waits for and between treatments, leading to worse outcomes for patients, are unacceptable. Improved care pathways are required to streamline the treatment journey. In this interview, Neal Navani, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses the new National Optimal Lung Cancer Pathway (NOLCP). This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

The 2017 National Lung Cancer Audit (NCLA) report launched at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland. The main findings of this report are discussed in this exciting interview with Paul Beckett, MD, FRCP, of the Care Quality Improvement Department, Royal College of Physicians, London, UK. Dr Beckett highlights the rates of curative surgery, 1-year survival, variations in performance geographically and access to a lung cancer Clinical Nurse Specialist. The full report can be found at www.rcplondon.ac.uk/projects/national-lung-cancer-audit. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin,…

The findings of the National Lung Cancer Audit (NCLA) annual reports provide a means to identify where lung cancer care can be improved, and then provide recommendations to aid in the improvement of services. In this interview, Paul Beckett, MD, FRCP, of the Care Quality Improvement Department, Royal College of Physicians, London, UK, discusses how the measures which the NLCA monitors will tie into achieving the National Optimal Lung Cancer Pathway (NOLCP). This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

The British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, hosted the launch of the latest National Lung Cancer Audit (NCLA) report. Speaking from the conference, Paul Beckett, MD, FRCP, of the Care Quality Improvement Department, Royal College of Physicians, London, UK, provides an overview of the NLCA, including what it is and why it is important in improving lung cancer care. Dr Beckett also passionately highlights the aims of the NCLA.

As traditional treatments for cancer are being surpassed by immunotherapies, the way in which healthcare providers deliver services must change. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from The Christie NHS Foundation Trust, Manchester, UK, discusses the transformations facing multidisciplinary teams in dealing with the care of cancer patients receiving immunotherapy. Dr Summers highlights the vital role of the pharmacist in the adoption of novel immunotherapies, particularly in reference to toxicities and patient education.

The landscape of NSCLC treatment is evolving rapidly. In this interview, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from The Christie NHS Foundation Trust, Manchester, UK, discusses exciting novel immunotherapies for NSCLC, including PD-1-targeting biologics such as pembrolizumab. Dr Summers explains the impacts of these new treatments on the clinical management of patients, including the tests required prior to commencing therapy. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.

The British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK revealed the latest clinical updates on prostate cancer treatment. In this video, Robert Jones, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK gives a summary of the key conclusions from the latest research that was discussed at the symposium.

Targeted therapy for prostate cancer is a promising field, which is set to grow in the coming year. Here, Robert Jones, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK discusses the latest news in this area, including the ongoing Phase II trial of olaparib, TOPARP (NCT01682772), and the potential of PTEN-PI3K pathway inhibitors. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.

The identification of effective systemic medications for prostate cancer has been relatively recent and this field is now making exciting advances. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Robert Jones, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK provides a captivating overview of the results of the recent STAMPEDE (NCT00268476) and LATITUDE (NCT01715285) trials of docetaxel and abiraterone, respectively, for patients with metastatic and/or high-risk disease. Dr Jones then discusses the preliminary results of which drug is better for this group and upcoming clinical trials of hormone receptor antagonists…

At the 2018 Gastrointestinal Cancers Symposium, David Ilson, MD, PhD, from the Memorial Sloan Kettering Cancer Center talks about a different number of strategies to individualize treatment and about the recently completed HER2 Trial.

The common discussion of where to start a patients dosage of regorafenib. Steven J. Cohen, MD, the Chief of the Medical Oncology and Hematology Division at Jefferson Health/Abington Hospital and Vice-Chair of the Department of Medical Oncology at Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, talks with us about how he believes the ReDOS study is eye opening and how it helped patients in the long term.

Determining the progression and the responses of Hepatocellular Carcinoma (HCC). Professor Andrew X. Zhu, MD, PhD from Harvard Medical School and also the Director of Liver Cancer Research, comes to use from the 2018 Gastrointestinal Cancers Symposium to talk about the ways we diagnose and assess the response in HCC.

The choice of first line therapy differs on tumor sidedness. Professor Alan P. Venook, MD, joins us from the 2018 Gastrointestinal Cancers Symposium and talks about the deciding factor when it comes to the first line of therapy for either left-sided or right-sided patients.

Sudipto Mukherjee, MD from Cleveland Clinics discusses promising novel agents that can change the treatment landscape and FLT3 and IDH1 inhibitors, luspatercept at the 2017 American Society of Hematology.

Jonathan Gerber, MD from Levine Cancer Institute discusses hopeful for the FDA approval of the IDH1 inhibitor and new generation of inhibitors like FLT3 are hopefully more effective at the 2017 American Society of Hematology.

The British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, had a record number of attendees, following a steady increase in delegates each year. Some of the reasons for its popularity are explained here by Jeanette Dickson, MD, FRCR, of East and North Hertfordshire NHS Foundation Trust, who highlights the important role which BTOG serves in providing a channel for multiprofessional communication. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, we asked a number of experts what the key unanswered question in lung cancer is currently. The general consensus was that there were many questions, but each speaker had their own take. Here, Jeanette Dickson, MD, FRCR, of East and North Hertfordshire NHS Foundation Trust, Stevenage, UK, gives her answer, covering the hot topic of lung cancer screening, as well as treatment combination and sequencing.

There have been great improvements in radiotherapy (RT) services in the UK over the past 10 years; however, there is still progress to be made, particularly in certain areas. In this informative interview, Jeanette Dickson, MD, FRCR, Vice President for Clinical Oncology of The Royal College of Radiologists, discusses the changes to RT services that could be made in order to improve patient care. Dr Dickson, of East and North Hertfordshire NHS Foundation Trust, Stevenage, UK, highlights the roll-out of new technologies, such as stereotactic ablative RT, and the equality of access of patients in all centers. This video was…

Radiotherapy (RT) services in England are being shaken up in a reorganization, which was a hot topic at the British Thoracic Oncology Group (BTOG) Annual Conference 2018. In this exciting interview, Jeanette Dickson, MD, FRCR, Vice President of Clinical Oncology for The Royal College of Radiologists, from East and North Hertfordshire NHS Foundation Trust, Stevenage, UK, provides an overview of the talk that she gave at the meeting on the planned changes to RT services and the benefits that it is hoped that these will bring, as well as the foreseen challenges. This video was recorded at the BTOG Annual…

Steve Williamson from the Northumbria Healthcare Trust, Newcastle upon Tyne, UK, and Chair of the 20 years anniversary British Oncology Pharmacy Association (BOPA) 2017 annual meeting in Glasgow talks to us about the great sessions taking place on day 2 of the BOPA 2017 meeting. The theme of this years meeting is Looking back, moving forward and is encouraging the oncology pharmacist community to reflect on progress made in the past 20 years and to consider where progress will be made in the future. Recorded at the BOPA 2017 meeting in Glasgow, UK.

Steve Williamson from the Northumbria Healthcare Trust, Newcastle upon Tyne, UK, and Chair of the 20 years anniversary British Oncology Pharmacy Association (BOPA) annual meeting in Glasgow, discusses his highlights from Day 1 of the meeting. Themes explored include oncology pharmacist career paths, sessions on the importance of the patient perspective, experience with biosimilars, the latest challenges in cancer research and the potential of big data in oncology. As well as summarising the key sessions, Steve Williamson describes his highlights from the breakout sessions that focussed on haematology, policy and access, and paediatrics.

Pharmacists are integral to providing and developing supportive care in cancer. In this interview, the essential roles of the pharmacist in regards to supportive cancer care are discussed by Richard Berman, FRCP from The Christie NHS Foundation Trust, Manchester, UK. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.

Supportive care for cancer is a relatively new area and is set to grow as the need for it increases. Here, Richard Berman, FRCP from The Christie NHS Foundation Trust, Manchester, UK discusses the changes required to implement widespread supportive care in cancer, including infrastructure. Dr Berman also remarks upon the current regulations for this topical area of care.

Supportive care for patients with cancer is becoming increasingly important, with advances in care meaning more people are surviving and living with cancer. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Richard Berman, FRCP from The Christie NHS Foundation Trust, Manchester, UK discusses the importance of supportive care in cancer to healthcare professionals and provides an overview of the new Enhanced Supportive Care initiative being run by NHS England.

Aaron Gerds, MD from Cleveland Clinics discusses new forms of interferon have improved side-effect profiles and pegylated interferon and ropeginterferon lasts much longer at the 2017 American Society of Hematology.

Sudipto Mukherjee, MD from Cleveland Clinics discusses personalized prediction model for Myelodysplastic Syndromes and certain mutations predict non-malignant conditions at the 2017 American Society of Hematology.

Jonathan Gerber, MD from Levine Cancer Institute discusses new agents becoming available for the 1st time in decades and what agents can be safely combined in pre & post transplant therapy at the 2017 American Society of Hematology.

Sudipto Mukherjee, MD from Cleveland Clinics discusses two areas that potentially cut down rehospitalizations and follow patients to be on top of their health and manage symptoms at the 2017 American Society of Hematology.

Aaron Gerds, MD from Cleveland Clinics discusses patients showed symptomatic relief in Phase I Trial of Glasdegib and 35% of patients had at least a 20% improvement in their symptom burden at the 2017 American Society of Hematology.

Jonathan Gerber, MD from Levine Cancer Institute discusses 9 out of 10 achieved remission with Hypomethylating agent and next phase is to expand as a viable approach for elderly patients at the 2017 American Society of Hematology.

Sudipto Mukherjee, MD from Cleveland Clinics discusses preliminary findings of unplanned hospital readmissions and conclusive data may identify patients to cut down readmission rates at the 2017 American Society of Hematology.

Aaron Gerds, MD from Cleveland Clinics discusses Phase 2 Trial of Glasdegib in myelofibrosis was not launched – due to modest overall response in clinical activity at the 2017 American Society of Hematology.

Sudipto Mukherjee, MD from Cleveland Clinics discusses predicting multiple rehospitalizations after initial admission – subsets of patients who have advanced hematologic malignancies at the 2017 American Society of Hematology.

Jonathan Gerber, MD from Levine Cancer Institute discusses changed the strategy of chemotherapy and transplants and gentle upfront then the intensive strategy for curative transplant at the 2017 American Society of Hematology.

Rafael Fonseca, MD from the Mayo Clinic in Phoenix, Arizona, discusses new information for normal plasma cell biology and findings were used to develop new treatments like, MCL-1 at the 2017 American Society of Hematology.

Masatoshi Kudo, MD from Kindai University, Japan discusses TACTICS trial demonstrates benefit with TACE plus Sorafenib in unresectable HCC at the 2018 Gastrointestinal Cancers Symposium.         keynote-062 trial, tactics trial, tace plus sorafenib, unresectable HCC, gastrointestinal, gastrointestinal cancers symposium

Masatoshi Kudo, MD from Kindai University, Japan discusses TACE new cancer region is not failure and TACE + Sorafenib should be continued even after new cancer at the 2018 Gastrointestinal Cancers Symposium.

Masatoshi Kudo, MD from Kindai University, Japan discusses TACE + Sorafenib may change standard in HCC and if overall survival data is positive then standard of care will change at the 2018 Gastrointestinal Cancers Symposium.

Rafael Fonseca, MD from the Mayo Clinic in Phoenix, Arizona, discusses real world outcomes for myeloma patients trial and phase 3 trial results can be reproduced using real world data from a database at the 2017 American Society of Hematology.

Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the Regorafenib Dose Optimization Study (ReDOS) and how a Weekly escalation Regorafenib 80 to 160 mg-day superior to start dose of 160 mg-day. Recorded at ASCO GI 2018.

Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the combination of Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer with an 8% Response Rate with an Overall Survival of 13-14 months. Recorded at ASCO GI 2018.

Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how it has shown a 55% Response Rate in MSI High patients. Recorded at ASCO GI 2018.

Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses Checking for CEA in Metastatic Anal Cancer and how it may Benefit as a Biologic Marker in Anal Cancer. This was recorded at ASCO GI 2018.

Aaron Gerds, MD from Cleveland Clinics discusses Glasdegib intended to be long-term goal for treating myelofibrosis and isolating the roots of the disease is a focus in the field going forward at the 2017 American Society of Hematology.

Aaron Gerds, MD from Cleveland Clinics discusses longer-lasting interferon being developed: Ropeginterferon and ongoing randomized trial in polycythemia vera at the 2017 American Society of Hematology.

David Feltquate Head of Early Clinical Development at BRISTOL-MYERS SQUIBB discusses the the phase 1b/2 open-label study which will explore the combination of standard chemotherapy and two immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40 in pancreatic cancer. The two agents are APX005M & Nivolumab and the trial is unique in that four institutions, The Parker Institute for Cancer Immunotherapy, the Cancer Research Institute, Bristol-Myers Squibb and Apexigen, are combining their efforts to speed the trial and results.

Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the ONC201 Safety and Advantages including No Hair Loss, No Mucositis, Stable Blood Counts, and potentially more Natural Killer Cells

Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the ONC201 Patient Disqualifiers such as Peritoneal Metastasis, Esophageal Metastasis and if the patient is Too Sick to Travel.

Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses moving ONC201 from Phase 2 to Phase 3 and how they need to Establish Better Quality of Life, Better Tumor Markers and that May Lead to Fastrack.

Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the the Patient Enrollment for Phase 2 ONC201 and the requirements such as Karnofsky Performance 60%+ and Good Kidney and Liver Performance

Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the Phase 2 ONC201 Patient Selection and other Neuroendocrine Tumors such as Desmoplastic Small Round Cell Tumor, Neuroblastoma, and Clear-Cell Carcinoma

Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the Phase 2 ONC201 Patient Selection and especially Pheochromocytoma and Paraganglioma patients.

Aaron Gerds, MD from Cleveland Clinics discusses results of Phase I trial in heavily pre-treated myelofibrosis and dysgeusia and muscle spasms were among the negative side-effects at the 2017 American Society of Hematology.

Mitsuo Hori, MD from Ibaraki Prefectural Central Hospital discusses results of randomized trial of ELd treatment and primary endpoint was met with ORR of 88 with ELd in Japanese patients at the 2017 American Society of Hematology.

Joshua Richter, MD from John Theurer Cancer Center discusses CAR-T Cell therapy as potential venue for multiple myeloma and bispecific antibody may provide immuno-oncology in safer venue at the 2017 American Society of Hematology.

Aaron Gerds, MD from Cleveland Clinics discusses phase I-II trial of Glasdegib in myelofibrosis and that Glasdegib is a Hedgehog Pathway Inhibitor at the 2017 American Society of Hematology.

Mitsuo Hori, MD from Ibaraki Prefectural Central Hospital discusses ELOQUENT-2 study in Japanese patients safety was consistent with patients in relapsed refractory myeloma at the 2017 American Society of Hematology.

Joshua Richter, MD from John Theurer Cancer Center discusses GBR 1342: A bispecific T cell engager that attaches to CD38 receptor at the 2017 American Society of Hematology.

Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC.

Robert Rifkin, MD from Rocky Mountain Cancer Center discusses FDA approval of several CAR-T Cell therapies and hope to make new therapies accessible to patients at the 2017 American Society of Hematology.

Mark Bustoros, MD from Dana-Farber Cancer Institute discusses new cancer research technologies in recent years and access new information and a better understanding of cancer progression at the 2017 American Society of Hematology.

Robert Rifkin, MD from Rocky Mountain Cancer Center discusses development of a predictive model of multiple myeloma patient outcomes and based on treatment class transitions using patient registry at the 2017 American Society of Hematology.

Robert Rifkin, MD from Rocky Mountain Cancer Center discusses baseline disease characteristics & diagnostic patterns for NDMM – observations over time in Cohort 1 and Cohort 2 at the 2017 American Society of Hematology.

Jens Lohr, MD from Dana-Farber Cancer Institute discusses blood biopsies instead of bone marrow and new findings from blood biopsy add to the information at the 2017 American Society of Hematology.

Mark Bustoros, MD from Dana-Farber Cancer Institute discusses center for prevention of progression of blood cancers and focused on precursor conditions of blood cancers at the 2017 American Society of Hematology.

Robert Rifkin, MD from Rocky Mountain Cancer Center discusses survival and depth of response in African American and Non-AA patients and conflicting data on the virulence of myeloma for African American patients at the 2017 American Society of Hematology.

Jens Lohr, MD from Dana-Farber Cancer Institute discusses cases when cell free DNA is most beneficial and specific patient populations and stage of disease at the 2017 American Society of Hematology.

Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Connect® multiple myeloma patient registry and eventually pool data from Connect® for a larger database of registry at the 2017 American Society of Hematology.

Joshua Richter, MD from John Theurer Cancer Center discusses next step for Phase 1 GBR 1342 studies and identifying the maximum tolerated dose to proceed to Phase 2 at the 2017 American Society of Hematology.

Mark Bustoros, MD from Dana-Farber Cancer Institute discusses collaborators provide samples to Dana Farber Institute and large amount of samples provides stronger results for Smoldering Multiple Myeloma at the 2017 American Society of Hematology.

Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses this phase 3 trial has shown improved overall survival and toxicity profile has been stable with prolonged exposure to drugs at the 2017 American Society of Hematology.

Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses phase 2 trials of BCMA targeted therapy and finding safety, toxicity, and efficacy in a larger patient population at the 2017 American Society of Hematology.

Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib is extraordinarily active in myeloma and mainstay drug for physicians and patients at the 2017 American Society of Hematology.

Jens Lohr, MD from Dana-Farber Cancer Institute discusses limitations of blood biopsy and that one must have enough circulating DNA in the bloodstream at the 2017 American Society of Hematology.

Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the first phase 3 trial of a new drug added to a standard and the must use triplet therapy early in the diseases course at the 2017 American Society of Hematology.

Joshua Richter, MD from John Theurer Cancer Center discusses inclusion and exclusion criteria of GBR 1342 and the trial designed for patients who have no proven therapy available at the 2017 American Society of Hematology.

Mark Bustoros, MD from Dana-Farber Cancer Institute discusses on how to improve the prediction of progression of multiple myeloma at the 2017 American Society of Hematology.

Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses data shows safety of drugs for clinicians & academia and how data is accessible to private practice clinicians and academia now at the 2017 American Society of Hematology.

Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib doing patterns and the data presented for appropriate dosing of Carfilzomib at the 2017 American Society of Hematology.

Jens Lohr, MD from Dana-Farber Cancer Institute discusses advantages of blood biopsy and how blood draw is comfortable and convenient for patients at the 2017 American Society of Hematology.

Joshua Richter, MD from John Theurer Cancer Center discusses GBR 1342 studies in phase 1 and search for the maximum tolerated dose at the 2017 American Society of Hematology.

Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses phase 2 trial of Dasatinib with Philadelphia Chromosome+ ALL and how the results were similar to studies with imatnib at the 2017 American Society of Hematology.

Mark Bustoros, MD from Dana-Farber Cancer Institute discusses largest study on genomic smoldering Multiple Myeloma and 135 patients were studied with 186 samples at the 2017 American Society of Hematology.

Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the analysis from the randomized phase 3 Aspire trial and Carfilzomib, Lenalidomide, & Dexamethasone V. Lenalidomide & Dexamethasone at the 2017 American Society of Hematology.

Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses trial combines Daratumumab with Carfilzomib & Dexamethasone and the first trial combining all drugs in a larger patient experience at the 2017 American Society of Hematology.

Robert Rifkin, MD from Rocky Mountain Cancer Center discusses poster #1 phase 2 study of Daratumumab+ CyBorD and the dose was split into two days to reduce infusion time at the 2017 American Society of Hematology.

Jens Lohr, MD from Dana-Farber Cancer Institute discusses cell free DNA sequencing and DNA is isolated in the bloodstream instead of bonemarrow at the 2017 American Society of Hematology.

John M Burke, MD from Rocky Mountain Cancer Centers discusses further promising studies in 2018 – CAR-T cell therapy, Polatuzumab, checkpoint inhibitorsat the 2017 American Society of Hematology.

Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses ongoing randomized studies of Selinexor and Selinexor with chemotherapy, single-agent activity, etc at the 2017 American Society of Hematology.

John M Burke, MD from Rocky Mountain Cancer Centers discusses CAR-T cell therapy with diffuse Large-B-cell Lymphoma and more CAR-T Cell products available in the near future at the 2017 American Society of Hematology.

Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses further immunotherapy research in 2018-19 and the incorporation of new drugs for newly diagnosed patients with ALL at the 2017 American Society of Hematology.

John M Burke, MD from Rocky Mountain Cancer Centers discusses lymphoid malignancies treatment developments and replacement of Bleomycin with Brentuximab Vedotin at the 2017 American Society of Hematology.

Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses developments of Phase 3 trial: BOSTON – Bortezomib in combination with Selinexor for treating myeloma at the 2017 American Society of Hematology.

Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses patients with Philadelphia Chromosome+ ALL can be cured and limited use of stem-cell transplants on 1st remission at the 2017 American Society of Hematology.

John M Burke, MD from Rocky Mountain Cancer Centers discusses new Phase 3 Murano trial for CLL and Venetoclax & Rituximab superior to Bendamustine & Rituximab at the 2017 American Society of Hematology.

Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses individualized medicine in 2018 and therapies based on tumor specimens, incorporation of patient input at the 2017 American Society of Hematology.

John M Burke, MD from Rocky Mountain Cancer Centers discusses monitor patients minimal residual disease status and maintenance doses of obinutuzumab & atezolizumab at the 2017 American Society of Hematology.

Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses successor trials from North American and European group and testing imatnib with chemotherapy backbones at the 2017 American Society of Hematology.

Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses Selinexor its mechanism of action and as it restores the activity of tumor-suppressant proteins at the 2017 American Society of Hematology.

Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses a new oral compound, Selinexor and how it can be safely combined with different drugs for efficacy at the 2017 American Society of Hematology.

John M Burke, MD from Rocky Mountain Cancer Centers discusses a new study with diffuse large B-cell lymphoma and improvements taking Polatuzumab with Bendamustine and Rituximab at the 2017 American Society of Hematology.

Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses subgroups of patients who benefit from interferon and delaying progression or progression-free survival at the 2017 American Society of Hematology.